Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP)

BACKGROUND: In recent times, anti-cancer treatments have focused on Fibroblast Growth Factor (FGF) and Vascular-Endothelial Growth Factor (VEGF) pathway inhibitors so as to target tumor angiogenesis and cellular proliferation. One such drug is Nintedanib; the present study evaluated the effectivenes...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:J Biomed Sci
Prif Awduron: da Silva, Raquel Frenedoso, Nogueira-Pangrazi, Ellen, Kido, Larissa Akemi, Montico, Fabio, Arana, Sarah, Kumar, Dileep, Raina, Komal, Agarwal, Rajesh, Cagnon, Valéria Helena Alves
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: BioMed Central 2017
Pynciau:
Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5429557/
https://ncbi.nlm.nih.gov/pubmed/28499383
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12929-017-0334-z
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg